<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> markers are playing an increasingly important role in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> detection and management </plain></SENT>
<SENT sid="1" pm="."><plain>These laboratory-based tests are potentially useful in screening for early <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, aiding <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis, determining prognosis, surveillance following curative surgery for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, up front predicting drug response or resistance, and monitoring therapy in advanced disease </plain></SENT>
<SENT sid="2" pm="."><plain>Clinically useful markers include fecal occult blood testing in screening for early <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, carcinoembryonic antigen in the management of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, both Î±-fetoprotein and human chorionic gonadotrophin in the management of patients with non-seminomatous <z:mpath ids='MPATH_310'>germ cell tumors</z:mpath>, CA 125 for monitoring therapy in patients with <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e>, <z:chebi fb="0" ids="50114">estrogen</z:chebi> receptors for predicting response to hormone therapy in <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, human epidermal growth factor receptor 2 for the identification of women with <z:hpo ids='HP_0003002'>breast cancer</z:hpo> likely to respond to trastuzumab (Herceptin) and KRAS mutational status for identifying patients with advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> likely to benefit from treatment with the anti-epidermal growth factor receptor antibodies, cetuximab and panitumumab </plain></SENT>
<SENT sid="3" pm="."><plain>Although widely used, the value of prostate-specific antigen screening in reducing mortality from <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> is unclear </plain></SENT>
</text></document>